Skip to main content

Taggar

andningsvägar

cancer

diabetes

forskning & utveckling

hjärta/kärl

ledning

mage/tarm

neurovetenskap

AstraZeneca 220 cancer 120 forskning & utveckling 111 hjärta/kärl 85 diabetes 59 andningsvägar 30 mage/tarm 14 neurovetenskap 11 FDA 10 onkologi 8 infektion 7 delårsrapport 7 seroquel 7 forskning 6 akut kranskärlssjudom 6 astma 6 Observationsstudie 6 medimmune 6 bokslutsrapport 5 influensavaccin 5 motavizumab 5 Tagrisso 5 egfr-testning 5 naloxegol 5 forxiga 5 ledning 5 RWE 5 vandetanib 5 bristol-myers squibb 4 fluenz 4 lungcancer 4 tc-5214 4 karolinska institutet 4 seroquel xr 4 ledgångsreumatism 4 antibiotika 4 fostamatinib 4 olaparib 4 slusg 3 kroniskt obstruktiv lungsjukdom 3 subvention 3 anders ekblom 3 antibiotikaresistens 3 egentlig depression 3 gefitinib 3 vimovo 3 styrelsen 3 japan 3 astra tech 3 crestor® 3 pathos 3 selumetinib 3 osimertinib 3 CVD-REAL 3 produkt 3 seroquel xr (quetiapin fumarat) 2 seroquel xl 2 smärta 2 Real World evidence 2 registerstudie 2 byetta 2 kina 2 slusg stipendium 2 recentin 2 life science 2 benralizumab 2 ticagrelor 2 bydureon 2 kvartalsrapport 2 återfall 2 saturn 2 samarbete 2 epanova 2 Brilique 2 mdd 2 läkemedelsförmånen 2 klopidogrel 2 fulvestrant 2 confirm 2 caprelsa 2 astrazenca 2 individanpassad behandling 2 opioider 2 entocort 2 axanum 2 patenttvist 2 tyskland 2 ardea biosciences 2 almedalen 2 typ2diabetes 2 targacept 2 acalabrutinib 2 jupiter 1 faslodex (fulvestrant) 1 monoterapi 1 den amerikanska läkemedelsmyndigheten 1 skelettmetastaser 1 roger henriksson 1 produktionsanläggning 1 gikt 1 cardiologföreningen 1 ovarian cancer 1 merck-avtal 1 savor 1 årsredovisning 2010 1 non-executive director 1 iressa 1 nytt läkemedel mot lungcancer 1 behandling lungcancer 1 målstyrt läkemedel 1 EGFR 1 nytt läkemedel lungcancer 1 cediranib 1 bevacizumab 1 scilifelab 1 yngre forskare 1 päivi tolstoy 1 tobias ankner 1 hans andersson 1 syntetisk kemi 1 torrent pharma 1 varumärkta generika 1 saxagliptin 1 blodsockerkontroll 1 blodsockerfall 1 viktökning 1 esc 1 ldl-c 1 gonorré 1 sepsis 1 livskvalitet lungcancer 1 ipass 1 lungcancersymtom 1 mcrc 1 complete response letter (crl) 1 u.s. food and drug administration (fda) 1 generiskt esomeprazolmagnesium 1 kanadensiska hälsovårdsministeriet 1 apotex inc (notice of compliance 1 noc) 1 internationell konkurrens 1 nikotinkanalsblockerare 1 läkemedel 1 DAISY 1 subventioner 1 UCR 1 zibotentan 1 biokemiska markörer 1 egfr-muterad 1 cytofab 1 azd9773 1 eurika 1 kombiglyze xr 1 klinisk forsk 1 pegasus 1 produktionschef 1 berzeliussamlingen 1 nya läkemedel 1 right honourable baroness shriti vadera 1 certriad 1 astrazeneca lund 1 arbetsmarknadsdagar 1 registreringsansökan 1 kastrationsresistent 1 fas 3-studie 1 hormonresistent 1 budesonid 1 mobil-app 1 opioidbehandling 1 nktr-118 1 forskningsportfölj 1 skatteärende 1 denosumab 1 amylin 1 patologi 1 NSCLC 1 egfr mutation 1 egfr positiv 1 komboglyze 1 caz-avi 1 hälsoekonomiska data 1 delårsrapport januari-september 2011 1 patientundersökning 1 david brennan 1 hudinfektioner 1 medicon village 1 translationell 1 illumina 1 årsredovisning 2011 1 antibiotikum 1 flumist 1 kvadrivalent 1 quetiapin fumarat 1 citizen petitions 1 renaissance 4 1 renaissance 5 1 formuleringspatent 1 citizens petition 1 prismodell 1 lesinurab 1 the medicines company 1 nda 1 amend 1 amylin pharmaceuticals 1 mdr-tb 1 mikael agaton 1 grymt fett 1 tonårshjärnan 1 per hamid ghatan 1 grymt fett en filmserie om tonårshjärnan 1 exacerbationer 1 pascal soriot 1 säsongsinfluensavaccin för barn som nässpray 1 säsongsinfluencavaccin 1 barninfluensavaccin 1 nässprayvaccin 1 influensanässpray 1 jonas bergh 1 bröstcancer utmärkelse 2012 1 sjukhusinfektioner 1 zinforo 1 mjukdelsinfektioner 1 ceftarolinfosamil 1 max planck institute 1 magnus björsne 1 per alfredsson 1 remissvar prismodell 1 pris läkemedel 1 strategiska centra 1 forsknings - och utvecklingscentra 1 bioläkemedel 1 tre strategiska centra 1 aks 1 exenatide 1 glp-1 agonister 1 cancerregister 1 svenska lungcancerstudiegruppen 1 non-small-cell lungcancer 1 motivationsstöd 1 patient websida 1 sekundärprevention 1 patientstöd 1 fluenz tetra 1 metreleptin 1 lipodystrofi 1 lesinurad 1 farxiga 1 xigduo 1 myalept 1 ann cairns 1 akuta koronara syndrom 1 metabola sjukdomar 1 immunoterapier 1 advaxis 1 sommarforskarskola 1 non-small cell lung cancer 1 astma/kol 1 gensekvensering 1 oic 1 hjärt-och kärlsjukdom 1 hjärinfarkt 1 biohub 1 bioventurehub 1 elisabeth björk 1 antaros 1 hha 1 healthy heart africa 1 världsdiabetesdagen 2014 1 moventig 1 Lynparza 1 opioidorsakad 1 pegasus-timi 1 e-brilique 1 Uppsala Clinical Research Center 1 mobiltelefonapplikation 1 SUPPORT-studien 1 ordnat införande Almedalen 1 QTERN 1 Zavicefta 1 moderna therapeutics 1 SvFP 1 kyntheum 1 brodalumab 1 Imfinzi 1 durvalumab 1 CVD-REAL Nordic 1 norge 1 osimertinub 1 innovation 1 eu 1 sponsring 1 patent 1 produktion 1 lund 1 forskare 1 stipendier 1 usa 1 hjärtinfarkt 1 stroke 1 kol 1 influensa 1 depression 1 antidepressiva läkemedel 1 tlv 1 beslut 1 alzheimers 1 äggstockscancer 1 södertälje 1 högkostnadsskyddet 1 collaboration 1 halvårsrapport 1 forskarstipendium 1 schizofreni 1 merck 1 läkemedelsforskning 1 pfizer 1 psoriasis 1 bakterier 1 karolinska universitetssjukhuset 1 artros 1 pa 1 delårsrapport januari - mars 1 h1n1 1 r&d 1 mölndal 1 generiska läkemedel 1 typ 2-diabetes 1 styrelseordförande 1 gener 1 apollo 1 hälsoekonomi 1 halvårsresultat 1 pet 1 mrsa 1 ny indikation 1 diagnostik 1 förstoppning 1 kranskärlsjukdom 1 invasiv behandling 1 journal of clinical oncology 1 avancerad hormonkänslig bröstcancer 1 first studien 1 dapagliflozin 1 corporate 1 asco 1 konkurrenskraften 1 läkemedelsforskningen 1 forskarkarriärer 1 stipendieprogram 1 rosuvastatinkalcium 1 hyperkolesterolemi 1 pluto-studien 1 vimovotm 1 nsaid 1 pozen 1 sumitomo 1 american college of rheumatology 1 2009 annual scientific meeting in philadelphia 1 leif johansson 1 zactima (vandetanib) 1 toprol-xl 1 vaccinet 1 inflammation 1 jan lundberg 1 stemi 1 rosuvastatin 1 arimidex 1 anastrozol 1 atac 1 bypass 1 kolorektalcancer 1 sjukhussjuka 1 avancerad bröstcancer 1 avastin 1 kvalitetsregister 1 blodförgiftning 1 ämnesomsättningssjukdomar 1 jupiter-studien 1 ämnesomsättningssjukdomar (emdac) 1 Visa alla taggar
US FDA approves Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer

US FDA approves Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer

Pressmeddelanden   •   Apr 19, 2018 08:01 CEST

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations, (exon 19 deletions or exon 21 L858R mutations), as detected by an FDA-approved test.

Updated overall survival data for Lynparza in BRCA-mutated HER2-negative metastatic breast cancer presented at AACR

Updated overall survival data for Lynparza in BRCA-mutated HER2-negative metastatic breast cancer presented at AACR

Pressmeddelanden   •   Apr 16, 2018 08:01 CEST

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial showing the final overall survival (OS) results for Lynparza (olaparib) in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, US, 14-18 April 2018.

1st-line Tagrisso demonstrates sustained benefit post progression in patients with EGFR-mutated non-small cell lung cancer

1st-line Tagrisso demonstrates sustained benefit post progression in patients with EGFR-mutated non-small cell lung cancer

Pressmeddelanden   •   Apr 13, 2018 16:58 CEST

AstraZeneca today presented new post-progression outcomes data from an exploratory analysis of the global Phase III FLAURA trial, which assessed the efficacy and safety of Tagrisso (osimertinib) as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

AstraZeneca’s early and late-stage oncology portfolio showcased at AACR annual meeting and ELCC

AstraZeneca’s early and late-stage oncology portfolio showcased at AACR annual meeting and ELCC

Pressmeddelanden   •   Apr 04, 2018 12:01 CEST

AstraZeneca and MedImmune, its global biologics research and development arm, will present updates from their early and late stage oncology pipelines at two major congresses this month. In total, 98 abstracts were accepted for the European Lung Cancer Conference (ELCC) in Geneva,11-14 April, and the American Association for Cancer Research (AACR) annual meeting in Chicago,14-18 April.

The European Medicines Agency accepts regulatory submission for Lynparza in BRCA-mutated, HER2-negative metastatic  breast cancer

The European Medicines Agency accepts regulatory submission for Lynparza in BRCA-mutated, HER2-negative metastatic breast cancer

Pressmeddelanden   •   Apr 03, 2018 08:03 CEST

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the European Medicines Agency has validated for review the Marketing Authorisation Application (MAA) for Lynparza (olaparib).

US FDA accepts Biologics License Application for moxetumomab pasudotox in hairy cell leukaemia

US FDA accepts Biologics License Application for moxetumomab pasudotox in hairy cell leukaemia

Pressmeddelanden   •   Apr 03, 2018 08:03 CEST

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an investigational anti-CD22 recombinant immunotoxin and a potential new medicine for the treatment of adult patients with hairy cell leukaemia (HCL).

Media no image
Michelle Werner ny marknadsbolagschef för AstraZeneca Nordic-Baltic
AstraZeneca provides update on MYSTIC trial timeline

AstraZeneca provides update on MYSTIC trial timeline

Pressmeddelanden   •   Mar 12, 2018 08:04 CET

AstraZeneca and MedImmune, today announced an updated timeline for the final analysis of the Phase III MYSTIC trial of Imfinzi (durvalumab). Based on current predictions, the final analysis of overall survival (OS) is now expected in the second half of 2018 (previously anticipated in the first half).

New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 inhibitors

New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 inhibitors

Pressmeddelanden   •   Mar 11, 2018 21:51 CET

Real-world evidence study of more than 400,000 patients with type-2 diabetes, 74% of whom did not have a history of established cardiovascular disease, supports the association of CV benefits with use of Farxiga Latest analysis includes heart attack and stroke endpoints, longer follow-up period and six additional countries across Asia Pacific, the Middle East and North America

The European medicines agency accepts regulatory submission for Forxiga in adults with type-1 diabetes

The European medicines agency accepts regulatory submission for Forxiga in adults with type-1 diabetes

Pressmeddelanden   •   Mar 05, 2018 14:46 CET

First European filing acceptance of a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in type-1 diabetes

AstraZeneca aims to advance clinical practice in CV risk management with new data at ACC 2018

AstraZeneca aims to advance clinical practice in CV risk management with new data at ACC 2018

Pressmeddelanden   •   Mar 05, 2018 14:42 CET

10 abstracts including three late breakers presenting new Phase III data and landmark real-world evidence from Asia, Middle East and North America

MedImmune to create stand-alone company for  early-stage inflammation and autoimmunity  biologics

MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics

Pressmeddelanden   •   Feb 28, 2018 08:03 CET

AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules fromits early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio.

Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer

Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer

Pressmeddelanden   •   Feb 23, 2018 13:37 CET

AstraZeneca and MSD’s new Lynparza tablet formulation recommended for maintenance therapy regardless of BRCA status

US FDA approves Imfinzi for unresectable Stage III non-small cell lung cancer

US FDA approves Imfinzi for unresectable Stage III non-small cell lung cancer

Pressmeddelanden   •   Feb 17, 2018 08:12 CET

Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo)

Selumetinib granted Orphan Drug Designation by the US FDA for neurofibromatosis type 1

Selumetinib granted Orphan Drug Designation by the US FDA for neurofibromatosis type 1

Pressmeddelanden   •   Feb 15, 2018 08:05 CET

AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease

Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease

Pressmeddelanden   •   Feb 07, 2018 08:04 CET

Study reveals prolonging treatment with Brilinta 60mg after one year, reduces risk of major adverse cardiac events (MACE) by 19% and coronary death by 36%1 Builds on analysis2 showing 5-year ischaemic risk post-heart attack and benefits of long-term cardiovascular (CV) protection with Brilinta 60mg

AstraZeneca PLC:s resultatrapport för helåret och fjärde kvartalet 2017

AstraZeneca PLC:s resultatrapport för helåret och fjärde kvartalet 2017

Pressmeddelanden   •   Feb 02, 2018 08:05 CET

Positiv utveckling avseende kommersiellt genomförande och kostnadsdisciplin; produktförsäljningen ökade under kvartalet. AstraZeneca står inför tillväxt i produktförsäljningen för helåret 2018

AstraZeneca reports top-line phase III KRONOS trial results for PT010 triple combination therapy in chronic obstructive pulmonary disease

AstraZeneca reports top-line phase III KRONOS trial results for PT010 triple combination therapy in chronic obstructive pulmonary disease

Pressmeddelanden   •   Jan 26, 2018 08:06 CET

AstraZeneca today announced top-line results from the Phase III KRONOS trial that showed PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6µg, using Aerosphere Delivery Technology, in a pressurised metered-dose inhaler or pMDI) demonstrated a statistically significant improvement compared with dual combination therapies in six out of seven lung function primary endpoints.

Media no image